Benitec Biopharma Inc. (BNTC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Benitec Biopharma Inc. (BNTC) trades at $11.44 with AI Score 25/100 (Grade F). Benitec Biopharma Inc. is a development-stage biotechnology company focused on developing genetic medicines using DNA-directed RNA interference. Market cap: $300M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 9, 2026Analyst Coverage for BNTC: BNTC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BNTC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BNTC: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Benitec Biopharma Inc. (BNTC) Healthcare & Pipeline Overview
Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference therapeutics for chronic and life-threatening conditions. Their pipeline focuses on genetic medicines, including BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection, positioning them within the innovative gene therapy market.
What Is the Investment Thesis for BNTC?
Benitec Biopharma presents a high-risk, high-reward investment profile typical of development-stage biotech companies. The core value driver lies in the successful clinical development and eventual commercialization of BB-301 for OPMD and BB-103 for chronic HBV. Positive clinical trial data for either program could serve as a significant catalyst, driving substantial stock appreciation. However, the company's negative gross margin of -11.9% and a profit margin of -8327.9% underscore the financial challenges inherent in drug development, requiring careful monitoring of cash burn and potential future capital raises. The low Beta of 0.12 suggests the stock is less volatile than the overall market, but this may not fully capture the inherent risks of biotechnology investments.
Based on FMP financials and quantitative analysis
BNTC Key Highlights
- Market capitalization of $300M, reflecting investor valuation of the company's pipeline and technology.
- Negative gross margin of -11.9%, indicative of the high costs associated with research and development in the biotechnology sector.
- Profit margin of -8327.9%, highlighting the company's current lack of revenue and significant investment in its drug development programs.
- Beta of 0.12, suggesting relatively low volatility compared to the broader market, but potentially masking the inherent risks of biotechnology investments.
- Focus on DNA-directed RNA interference (ddRNAi) technology, positioning the company in the innovative gene therapy space.
Who Are BNTC's Competitors?
BNTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SCPH scPharmaceuticals Inc. | $5.67 | +0.00% | $302M | 69 |
| CGEN Compugen Ltd. | $2.34 | -3.31% | $221M | 76 |
| GNFT GNFT | $8.95 | +4.07% | $446M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
| MDXG MiMedx Group, Inc. | $4.13 | -0.96% | $615M | 93 |
| CRMD CorMedix Inc. | $8.05 | +1.39% | $632M | 95 |
| RIGL Rigel Pharmaceuticals, Inc. | $36.82 | -2.59% | $681M | 94 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BNTC's Key Strengths?
- Proprietary DNA-directed RNA interference (ddRNAi) technology.
- Pipeline of genetic medicine candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
- Focus on rare diseases, potentially leading to orphan drug designation.
What Are BNTC's Weaknesses?
- Development-stage company with no approved products and no recurring revenue.
- High cash burn and reliance on equity financing.
- Significant regulatory and clinical trial risks.
- Small number of employees (16), potentially limiting operational capacity.
What Could Drive BNTC Stock Higher?
- Clinical trial data releases for BB-301 in OPMD.
- Clinical trial data releases for BB-103 in chronic HBV infection.
- Potential strategic partnerships or collaborations.
- Advancements in the development of the ddRNAi platform.
What Are the Key Risks for BNTC?
- Negative return on equity (-34.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug candidates.
- Competition from other biotechnology companies.
- High cash burn and reliance on equity financing.
- Patent challenges or expiration of key patents.
What Are the Growth Opportunities for BNTC?
- BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD): OPMD is a rare genetic disorder with limited treatment options, representing a significant unmet medical need. If BB-301 demonstrates efficacy and safety in clinical trials, it could capture a substantial portion of this market. The OPMD market is estimated to grow as awareness and diagnostic capabilities improve, potentially reaching hundreds of millions of dollars. The timeline for commercialization depends on successful clinical trial outcomes, with potential for market entry within the next 3-5 years.
- BB-103 for Chronic Hepatitis B Virus (HBV) Infection: Chronic HBV infection affects millions of people worldwide, and current treatments are not always effective. BB-103 has the potential to offer a new therapeutic approach by targeting the viral RNA. The global market for HBV treatments is substantial, exceeding billions of dollars annually. Successful development and approval of BB-103 could provide Benitec with a significant revenue stream. Clinical trials are ongoing, with potential for market entry in 5-7 years if successful.
- Expansion of ddRNAi Platform: Benitec's DNA-directed RNA interference (ddRNAi) platform has the potential to be applied to a wide range of genetic diseases. The company could expand its pipeline by developing new ddRNAi-based therapeutics for other indications. This would diversify the company's risk and increase its long-term growth potential. The market for gene therapies is expected to continue to grow rapidly, providing opportunities for Benitec to leverage its platform.
- Strategic Partnerships and Collaborations: Benitec could pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships could provide access to additional funding, expertise, and resources. The biotechnology industry is characterized by collaborations, and Benitec could benefit from leveraging external expertise.
- Orphan Drug Designation and Regulatory Advantages: BB-301 for OPMD may be eligible for orphan drug designation, which provides regulatory advantages such as market exclusivity and tax credits. These advantages can significantly enhance the commercial potential of the drug. Orphan drug designation is often granted for drugs targeting rare diseases, and Benitec could leverage this to its advantage.
What Opportunities Does BNTC Have?
- Successful clinical development and commercialization of BB-301 and BB-103.
- Expansion of ddRNAi platform to develop new therapies for other genetic diseases.
- Strategic partnerships and collaborations with other biotechnology and pharmaceutical companies.
- Orphan drug designation and regulatory advantages for BB-301.
What Threats Does BNTC Face?
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug candidates.
- Competition from other biotechnology companies developing similar therapies.
- Patent challenges or expiration of key patents.
- Difficulty raising capital to fund ongoing operations.
What Are BNTC's Competitive Advantages?
- Proprietary DNA-directed RNA interference (ddRNAi) technology platform.
- Patent protection for its drug candidates and technology.
- Focus on rare diseases with limited treatment options, potentially leading to orphan drug designation.
What Does BNTC Do?
Benitec Biopharma Inc., founded in 1995 and headquartered in Hayward, California, is a development-stage biotechnology company dedicated to creating novel genetic medicines. The company focuses on utilizing DNA-directed RNA interference (ddRNAi) to develop therapies for chronic and life-threatening human conditions. ddRNAi is a gene-silencing technology that aims to reduce the expression of disease-causing genes. Benitec's primary focus is on advancing its pipeline of ddRNAi-based therapeutics. Their lead product candidate, BB-301, is an adeno-associated virus (AAV) based gene therapy agent designed to treat oculopharyngeal muscular dystrophy (OPMD), a rare genetic disorder causing progressive muscle weakness. Another key program is BB-103, which is being developed for the treatment of chronic hepatitis B virus (HBV) infection. As a development-stage company, Benitec Biopharma is currently focused on preclinical and clinical development, with no products yet approved for commercial sale. The company's strategy involves leveraging its ddRNAi platform to create innovative therapies for diseases with significant unmet medical needs.
What Products and Services Does BNTC Offer?
- Develops novel genetic medicines using DNA-directed RNA interference (ddRNAi).
- Focuses on therapies for chronic and life-threatening human conditions.
- Develops BB-301, an adeno-associated virus (AAV) based gene therapy for treating oculopharyngeal muscular dystrophy (OPMD).
- Develops BB-103 for the treatment of chronic hepatitis B virus (HBV) infection.
- Utilizes gene-silencing technology to reduce the expression of disease-causing genes.
- Conducts preclinical and clinical development of its drug candidates.
How Does BNTC Make Money?
- Focuses on research and development of genetic medicines.
- Generates revenue through potential future licensing agreements or commercialization of approved products.
- Funds operations through equity financing and potential future partnerships or grants.
What Industry Does BNTC Operate In?
Benitec Biopharma operates within the biotechnology industry, a sector characterized by high innovation, long development timelines, and significant regulatory hurdles. The market for gene therapies is rapidly expanding, driven by advancements in technology and a growing understanding of genetic diseases. Competition is intense, with numerous companies pursuing similar approaches. Benitec's focus on ddRNAi differentiates it from companies using other gene therapy modalities. The biotechnology industry is subject to stringent regulatory oversight by agencies such as the FDA, requiring extensive clinical trials to demonstrate safety and efficacy.
Who Are BNTC's Key Customers?
- Patients suffering from oculopharyngeal muscular dystrophy (OPMD).
- Patients suffering from chronic hepatitis B virus (HBV) infection.
- Potential future patients with other genetic diseases treatable with ddRNAi technology.
ROE -35%Key Financial Metrics
Return on equity for Benitec Biopharma Inc. stands at -34.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 56.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.4%, the inverse of the P/E and a quick read on earnings relative to price.
Benitec Biopharma Inc. (BNTC) Valuation Context
Valued at $300M, BNTC is classified as a small-cap stock. Relative to its peer group, BNTC's quantitative score of 25/100 is below the peer average of 72/100.
Company Profile
Benitec Biopharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hayward, US. The company is led by CEO Jerel A. Banks. BNTC has traded publicly since 2014.
F-Score 3/9Financial Health
Benitec Biopharma Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 67.77 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Benitec Biopharma Inc. revenue of about $25.4M for fiscal 2026, with EPS near $-1.02. The estimate reflects 6 contributing analysts.
BNTC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in gene therapy.
- Analysts are optimistic about upcoming clinical trial results, which could validate their innovative approach.
- Increased social media engagement suggests growing interest and support from retail investors.
Bear Case
- Concerns about the company's cash runway have surfaced, raising questions about its ability to fund ongoing projects.
- Negative sentiment from some community members points to skepticism regarding the timeline for product development.
- Recent regulatory challenges have created uncertainty around the approval process for key therapies.
- Market perception remains cautious, reflecting broader industry concerns about biotech volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $556,000 | -$16M | -$0.39 |
Based on FMP financials and quantitative analysis
BNTC Latest News
BNTC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BNTC.
Price Targets
Wall Street price target analysis for BNTC.
BNTC MoonshotScore
What does this score mean?
The MoonshotScore rates BNTC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Benitec Biopharma Inc. Analysis
Leadership: Jerel A. Banks
CEO
Jerel A. Banks serves as the CEO of Benitec Biopharma Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on corporate strategy, business development, and financial management. Prior to joining Benitec, Banks held leadership positions at various biotech companies, where he was responsible for driving growth and executing strategic initiatives. He brings a wealth of knowledge in drug development, regulatory affairs, and commercialization to Benitec Biopharma.
Track Record: Since becoming CEO of Benitec Biopharma, Jerel A. Banks has focused on advancing the company's pipeline of genetic medicine candidates, including BB-301 and BB-103. He has overseen the execution of clinical trials and the pursuit of strategic partnerships. Under his leadership, Benitec has continued to develop its proprietary ddRNAi technology platform. Banks is managing a small team of 16 employees.
What Investors Ask About Benitec Biopharma Inc. (BNTC) — Healthcare
What does the AI Score mean for BNTC?
BNTC holds an AI Score of 25/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Benitec Biopharma Inc. is a development-stage biotechnology company focused on developing genetic medicines using DNA-directed RNA interference. Their pipeline includes BB-301 for oculopharyngeal …
What does Benitec Biopharma Inc. do?
Benitec Biopharma Inc. is a development-stage biotechnology company focused on developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company's primary focus is on advancing its pipeline of ddRNAi-based therapeutics, including BB-301 for oculopharyngeal muscular dystrophy (OPMD) and BB-103 for chronic hepatitis B virus (HBV) infection.
What do analysts say about BNTC stock?
As a development-stage biotechnology company, analyst coverage of Benitec Biopharma Inc. (BNTC) may vary. Generally, analysts focus on the company's clinical trial progress, regulatory milestones, and financial runway. Key valuation metrics often include the potential market size for BB-301 and BB-103, as well as the likelihood of successful clinical development and regulatory approval.
What are the main risks for BNTC?
The main risks for Benitec Biopharma Inc. are typical of development-stage biotechnology companies. These include the risk of clinical trial failures or delays, regulatory hurdles and potential rejection of drug candidates, competition from other biotechnology companies developing similar therapies, and the risk of patent challenges or expiration of key patents.
What are the key factors to evaluate for BNTC?
Benitec Biopharma Inc. (BNTC) holds an AI score of 25/100 (low). Not financial advice.
How frequently does BNTC data refresh on this page?
BNTC's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BNTC's recent stock price performance?
Benitec Biopharma Inc. (BNTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DNA-directed RNA interference (ddRNAi) technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BNTC overvalued or undervalued right now?
Benitec Biopharma Inc. (BNTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BNTC before investing?
Before investing in Benitec Biopharma Inc. (BNTC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.